Biorestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Key Stats

• Today's Range: $1.50 to $1.54
• 50-Day Range: $1.41 to $1.72
• 52-Week Range: $1.21 to $2.55
• Volume: 23,781 shs
• Average Volume: 46,651 shs
• Market Capitalization: $12.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Biorestorative Therapies Stock Analysis - MarketRank™

Biorestorative Therapies scored higher than 51% of companies evaluated by MarketBeat, and ranked 564th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Biorestorative Therapies.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biorestorative Therapies are expected to grow in the coming year, from ($1.43) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biorestorative Therapies is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biorestorative Therapies is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biorestorative Therapies has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.86% of the float of Biorestorative Therapies has been sold short.

Short Interest Ratio / Days to Cover

Biorestorative Therapies has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biorestorative Therapies has recently decreased by 9.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biorestorative Therapies does not currently pay a dividend.

Dividend Growth

Biorestorative Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.86% of the float of Biorestorative Therapies has been sold short.

Short Interest Ratio / Days to Cover

Biorestorative Therapies has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biorestorative Therapies has recently decreased by 9.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.31

News Sentiment

Biorestorative Therapies has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Biorestorative Therapies this week, compared to 1 article on an average week.

Search Interest

1 people have searched for BRTX on MarketBeat in the last 30 days.

MarketBeat Follows

10 people have added Biorestorative Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biorestorative Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.80% of the stock of Biorestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.38% of the stock of Biorestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

Biorestorative Therapies' stock was trading at $1.43 at the beginning of 2025. Since then, BRTX stock has increased by 7.0% and is now trading at $1.53.

How were Biorestorative Therapies' earnings last quarter?

Biorestorative Therapies, Inc. (NASDAQ:BRTX) announced its earnings results on Tuesday, August, 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.11. The firm earned $0.30 million during the quarter, compared to analysts' expectations of $0.34 million. Biorestorative Therapies had a negative net margin of 1,772.40% and a negative trailing twelve-month return on equity of 137.00%.
Read the conference call transcript.

Is Biorestorative Therapies doing a stock buyback?

Biorestorative Therapies' board initiated a stock buyback program on Tuesday, June 17th 2025, which authorizes the company to buy back $2,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 15.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its shares are undervalued.

Who are Biorestorative Therapies' major shareholders?

Top institutional investors of Biorestorative Therapies include StoneX Group Inc. (0.50%).
View institutional ownership trends.

How do I buy shares of Biorestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biorestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biorestorative Therapies investors own include NVIDIA (NVDA), Micron Technology (MU), PayPal (PYPL), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), Broadcom (AVGO) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BRTX
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: 631-760-8100
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.98 million
• Net Margins: -1,772.40%
• Pretax Margin: -1,772.40%
• Return on Equity: -137.00%
• Return on Assets: -88.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.07
• Quick Ratio: 2.07

Sales & Book Value

• Annual Sales: $605.20 thousand
• Price / Sales: 20.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 2.51

Miscellaneous

• Outstanding Shares: 7,978,000
• Free Float: 5,521,000
• Market Cap: $12.21 million
• Optionable: Not Optionable
• Beta: 76.70